

Characteristics of Signal Transduction


✓ Signal Amplification

e.g. albuterol

✓ Spare receptors


insulin spare R_s = 99%

β -adrenoceptors = 5-10%



Desensitization, & Down-Regulation of Receptors

- ***tachyphylaxis***: repeated administration of the agonist lead to decrease in responsiveness of R_s



- ***Refractory***
- ***Up-regulation of receptors***






Dose-Response Relationships

- *Graded dose-response curve (DRC)*
- *Potency amount of drug required to produce a given response & used to determine ED_{50}*
 - Candesartan 4 - 32 mg**
 - Irbisartan 75 – 300 mg*
- *Efficacy: the magnitude of response*
- *Maximal efficacy E_{max}*




Dose-Response Relationships

A



The EC₅₀ is the concentration of the drug that produces a response equal to 50% of the maximal response.


B



The potency of drugs can be compared using the EC₅₀: the smaller the EC₅₀, the more potent the drug.



Drug A is more potent than Drug B, but both show the same efficacy.

Drug C shows lower potency and lower efficacy than Drugs A and B.





Effect of Drug Concentration on Receptor Binding









Relationship of Drug Binding to Pharmacologic Effect

- ❖ K_d value used to determine affinity
- ❖ The higher the K_d , the weaker the interaction, the lower the affinity
- ❖ The magnitude of response is proportional to the amount of Rs bound
- ❖ E_{max} represent full occupation of Rs

$$\frac{[E]}{[E_{max}]} = \frac{[D]}{K_d + [D]}$$

- ❖ **Affinity should be related to potency of drug for causing physiologic response**







Intrinsic activity represents the ability of a D to act as:

I- Full Agonists

intrinsic activity = 1


II- Partial Agonists

intrinsic activity > 0 & < 1


III- Inverse Agonists

*Spontaneous conversion from R to R**

intrinsic activity < 0




Effects of Partial Agonists




Competitive antagonism

- *Competitive --- Surmountable*
- *Competes with agonist in reversible fashion for same receptor site*
- *Necessary to have higher concentration of agonist to achieve same response*





B. Competitive antagonism




Noncompetitive antagonism

- *Noncompetitive --- Insurmountable*
- *Antagonist binds to a site different to that of an agonist*
- *No matter how much agonist -- antagonism cannot be overcome*




Antagonists

- I- Competitive Antagonists*
- II- Irreversible Antagonists*
- III- Allosteric Antagonists*
- IV- Functional or Chemical Antagonists*



Therapeutic Index

A Warfarin: Small therapeutic index



B Penicillin: Large therapeutic index

